Cerity Partners’s Cytek Biosciences CTKB Stock Holding History

Cerity Partners’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$129K	Sell	29,053 -29,070	-50%	-$124K	﹤0.01%	3171
2026 Q1	$254K	Buy	58,123 +8,595	+17%	+$40.6K	﹤0.01%	2727
2025 Q4	$250K	Sell	49,528 -2,461	-5%	-$11.4K	﹤0.01%	2513
2025 Q3	$180K	Buy	51,989 +627	+1%	+$2.35K	﹤0.01%	2529
2025 Q2	$175K	Buy	+51,362	New	+$171K	﹤0.01%	2389
2024 Q3	–	Sell	-11,815	Closed	-$65.9K	–	2552
2024 Q2	$65.9K	Buy	+11,815	New	+$71K	﹤0.01%	2149

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Cerity Partners's CTKB Position: Q2 2026 in Review

Cerity Partners reduced its Cytek Biosciences (CTKB) stake by 50% in Q2 2026, selling an estimated $124K and leaving 29,053 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #3171.

Cerity Partners first reported a position in CTKB in Q2 2024 and has held it in 6 quarters since. The position peaked at $254K in Q1 2026. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Cerity Partners held 29,053 shares of Cytek Biosciences worth $129K as of Q2 2026.
Cerity Partners sold 29,070 Cytek Biosciences shares in Q2 2026, an estimated $124K.
Cytek Biosciences made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3171 holding.
Cerity Partners first reported a position in Cytek Biosciences in Q2 2024 and has held it in 6 quarters since.
Cerity Partners's Cytek Biosciences position peaked at $254K in Q1 2026.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.